舒泰神：公司将继续推进BDB-001相关适应症的临床试验进展

Core Viewpoint - The company Shutaishen has provided insights on its drug BDB-001, highlighting its differences from AVACOPAN in terms of molecular structure, mechanism of action, and clinical characteristics [2] Group 1: Drug Development - BDB-001 is a large molecule antibody inhibitor targeting the C5a factor, expected to block the activity of the C5a/C5aR1 and C5a/C5aR2 pathways [2] - The company will continue to advance the clinical trials for BDB-001 related indications and encourages stakeholders to monitor future regular reports and project progress announcements [2]